- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
Background: Tropomyosin receptor kinase B (TrkB), encoded by NTRK2, is a neurotrophic receptor (NTRs) in the brain and is highly enriched in the neocortex, hippocampus, striatum, and brainstem, and altered TrkB expression is implicated in CNS pathologies e.g. Parkinson’s disease. The tyrosine kinase receptor TrkB, is activated specifically by brain derived growth factor and neurotrophin 4 (BDNF and NT4). BDNF binding to TrkB triggers its dimerization and autophosphorylation, resulting in activation of the three major signaling pathways involving mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and phospholipase C-g1 (PLC-γ1), mediating neural differentiation, survival, and neurogenesis. TrkA and TrkB are known to operate as proto-oncogenes contributing to cell migration and invasion as well as neovascularization in various types of cancer.
Recombinant human TRK-B (neurotrophic tyrosine kinase, receptor, type 2 / tyrosine kinase receptor B), protein kinase domain, recombinant and active enzyme, N-terminal GST-HIS6 fusion protein with a Thrombin and 3C cleavage site, expressed in Sf9 insect cells
Theoretical MW : 66.818 kDa (fusion proteins)
Expression system: Baculovirus infected Sf9 cells
Purification: GST-Affinity Chromatography
Activation: in vitro auto-activation
Storage buffer: 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT, 15 mM reduced glutathione, 20% glycerol
Protein concentration: 0.133 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MSFC membrane
Specific activity : 140,000 pmol/mg min
Entrez Gene ID 4915
UniProtKB Q16620
Ordering information: shipped on dry ice
Seong Su Kang, Zhentao Zhang, Xia Liu, Fredric P. Manfredsson, Matthew J. Benskey, Xuebing Cao, Jun Xu, Yi E. Sun, Keqiang Ye (2017) “TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease” Proc Natl Acad Sci U S A.; 114(40): 10773–10778.
Lange AM, Lo HW (2018) “Inhibiting TRK Proteins in Clinical Cancer Therapy.” Cancers (Basel). 10(4).
Vivek K. Gupta, Yuyi You, Veer Bala Gupta, Alexander Klistorner, Stuart L. Graham (2013) “TrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders” Int J Mol Sci. 14(5): 10122–10142
Welcome Login
Contact us
Follow us